Sign In
Buy URGN
$26.60
+0.0600 (+0.226%)
At Close: Jun 03, 2026
UROGEN PHARMA (URGN) Reports Q4 Loss, Tops Revenue Estimates
10:13am, Thursday, 18'th Mar 2021
UROGEN PHARMA (URGN) delivered earnings and revenue surprises of -5.34% and 10.46%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
UroGen Pharma: Q4 Earnings Insights
08:17am, Thursday, 18'th Mar 2021
Shares of UroGen Pharma (NASDAQ:URGN) rose 3.6% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 25.81% year over year to ($1.38), which miss
UroGen Pharma Announces $75 Million of Non-Dilutive Funding from RTW Investments
07:30am, Thursday, 18'th Mar 2021
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic dis
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic dis
UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
08:00am, Friday, 05'th Mar 2021
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN) a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic dise
Jelmyto And UGN-102 Will Likely Drive Strong Returns For UroGen Shareholders
02:07pm, Monday, 01'st Mar 2021
UroGen is using its proprietary reverse thermal gel technology to pioneer a line of therapies for upper urinary tract cancers that are substantially better than current options.
URGN Is Worth $50/Share Should It Trade At Revenue Multiples Consistent With Its Peers
03:00pm, Sunday, 10'th Jan 2021
UroGen's Jelmyto, approved April 2020 for LG-UTUC, has a J code effective 1/1/2021 allowing for dramatically more convenient coding & reimbursement. Revenues should be about $115,000/patient as labell
UroGen Pharma to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference
08:00am, Wednesday, 06'th Jan 2021
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq:URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic dise
UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
08:00am, Friday, 04'th Dec 2020
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic dis
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN) a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic dise
UroGen Pharma Announces November 2020 Conference Schedule
08:00am, Tuesday, 10'th Nov 2020
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq:URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic dise
UroGen Pharma's (URGN) CEO Liz Barrett on Q3 2020 Results - Earnings Call Transcript
03:02pm, Monday, 09'th Nov 2020
UroGen Pharma's (URGN) CEO Liz Barrett on Q3 2020 Results - Earnings Call Transcript
Recap: UroGen Pharma Q3 Earnings
08:33am, Monday, 09'th Nov 2020
Shares of UroGen Pharma (NASDAQ:URGN) were unchanged after the company reported Q3 results.
